Based on the Delcath Systems Inc stock forecast from 3 analysts, the average analyst target price for Delcath Systems Inc is USD 22.00 over the next 12 months. Delcath Systems Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Delcath Systems Inc is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Delcath Systems Inc’s stock price was USD 11.40. Delcath Systems Inc’s stock price has changed by +9.72% over the past week, -9.38% over the past month and +141.01% over the last year.
No recent analyst target price found for Delcath Systems Inc
No recent average analyst rating found for Delcath Systems Inc
Company Overview Delcath Systems Inc
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York. Read Less
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-d...Read More
Frequently Asked Questions About Delcath Systems Inc (DCTH) Stock
Based on ratings from 3 analysts Delcath Systems Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on DCTH's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for DCTH is USD 22.00 over the next 12 months. The maximum analyst target price is USD 24 while the minimum anlayst target price is USD 21.
DCTH stock's Price/Earning ratio is 0.60.
Our analysis grades DCTH stock's Price / Earning ratio at C. This means that DCTH stock's Price/Earning ratio is above 26% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this DCTH may be undervalued for its sector.
The last closing price of DCTH's stock was USD 11.40.
The most recent market capitalization for DCTH is USD 0.47B.
Based on targets from 3 analysts, the average taret price for DCTH is projected at USD 22.00 over the next 12 months.
This means that DCTH's stock price may go up by +92.98% over the next 12 months.
We can't find any ETFs which contains Delcath Systems Inc's stock.
As per our most recent records Delcath Systems Inc has 96 Employees.
Delcath Systems Inc's registered address is 1633 Broadway, New York, NY, United States, 10019.
You can get more information about it from Delcath Systems Inc's website at https://www.delcath.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Delcath Systems Inc (DCTH) Stock
Based on ratings from 3 analysts Delcath Systems Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on DCTH's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for DCTH is USD 22.00 over the next 12 months. The maximum analyst target price is USD 24 while the minimum anlayst target price is USD 21.
DCTH stock's Price/Earning ratio is 0.60.
Our analysis grades DCTH stock's Price / Earning ratio at C. This means that DCTH stock's Price/Earning ratio is above 26% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this DCTH may be undervalued for its sector.
The last closing price of DCTH's stock was USD 11.40.
The most recent market capitalization for DCTH is USD 0.47B.
Based on targets from 3 analysts, the average taret price for DCTH is projected at USD 22.00 over the next 12 months.
This means that DCTH's stock price may go up by +92.98% over the next 12 months.
We can't find any ETFs which contains Delcath Systems Inc's stock.
As per our most recent records Delcath Systems Inc has 96 Employees.
Delcath Systems Inc's registered address is 1633 Broadway, New York, NY, United States, 10019.
You can get more information about it from Delcath Systems Inc's website at https://www.delcath.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for DCTH !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
